查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1561496

2024-2032 年按产品、应用、最终用户和地区分類的药物器材组合产品市场报告

Drug Device Combination Products Market Report by Product, Application, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3个工作天内

价格

2023年，全球药物器材组合产品IMARC Group规模达到1,553亿美元。药物输送系统的技术进步、慢性病盛行率上升、老年人口增加、个人化医疗需求激增、关键参与者的策略合作、医疗保健支出扩大、对微创手术的偏好以及在不同治疗领域扩大产品应用等都是其中的一些因素。

药物器材组合产品市场分析：

  • 主要市场驱动因素：根据药物器材组合产品市场分析，慢性病盛行率的上升以及对更有效、更方便的治疗方案的需求正在推动对药物器材组合产品的需求。全球老年人口的快速成长也刺激了药物器材组合产品市场的成长，随着老年人产生更多与生活方式相关的健康问题，这增加了对新医疗方法的需求。此外，公司越来越多地采用个人化医疗方法，包括用于标靶治疗的药物输送装置，这进一步积极促进了药物设备组合产品的市场份额。推动药物器材组合产品市场前景的其他因素包括组合产品开发的监管支援和经济激励，以及发展中国家不断扩大的医疗保健支出。
  • 主要市场趋势：根据药物器械组合产品市场研究，药物器械组合产品最显着的趋势是人们对穿戴式药物输送设备的兴趣日益增长，以改善患者的活动能力和生活品质。推动药物设备组合产品市场价值的另一个因素是越来越多地使用智慧型设备来控制患者的依从性和治疗反应，并根据需要即时调整剂量和治疗方案。与此一致，将数位技术融入产品及其利用物联网（IoT）的能力增加了患者参与度和结果监测，这进一步推动了药物器械组合产品的市场需求。除此之外，三维（3D）列印技术的进步为基于患者解剖结构和需求的个人化设备製造创造了新的机会，这有助于药物设备组合产品市场的预测。
  • 地理趋势：根据药物器材组合产品市场研究报告，由于发达的医疗基础设施、广泛的研发投资和宽鬆的监管，北美是该行业的领先地区。除此之外，该地区巨大的疾病负担所支撑的高额医疗支出推动了新兴治疗替代方案的采用，这进一步推高了药物器械组合产品的市场价格。鑑于其强大的医疗保健系统以及对品质和安全的关注，欧洲在药物器材组合产品市场细分方面紧随其后。另一方面，亚太地区是一个日益增长的市场，受到医疗支出不断增加、现代治疗方法知识不断增加以及慢性病数量不断增加的支持，这进一步增加了药物器械组合产品市场收入。
  • 竞争格局：根据药物器材组合产品市场统计，市场上的一些主要参与者包括雅培实验室、百特国际公司、拜耳公司、贝克顿迪金森公司、波士顿科学公司、葛兰素史克公司、强生公司、美敦力公司plc、Novartis AG、Smith & Nephew plc、Stryker Corporation、Terumo Corporation 等。
  • 挑战与机会：根据药物器材组合产品市场概况，市场面临许多挑战，包括高水准的监管要求，这可能导致开发时间增加，从而增加成本。确保药物和器械的兼容性，必须满足所有安全性和有效性标准，是一个很大的困难。许多相同的因素都提供了创新的机会。特别是提高设备效率和增加患者便利性的新方法。一个有利的机会也是为那些对先进医疗解决方案有潜在需求但尚未解决的国家补充市场。

药物器材组合产品市场趋势：

药物输送系统的技术进步

新的药物输送系统，包括自动注射器、吸入器和输液泵，正在改变医疗保健的管理方式，使其更加精确、方便和有效。精确、有针对性的药物输送使患者能够达到预期的治疗效果，同时将发生药物不良反应的可能性降到最低。例如，自动注射器的使用极大地改变了患者日常服药的方式，让使用者以舒适、简单的方式自行给药。此药物输送系统有助于提高治疗依从性并降低住院费用。针对呼吸系统问题的先进吸入器，例如配备剂量计数器或数位感测器的吸入器，可以提供回馈和监测，使患者能够独立管理药物管理。

慢性病盛行率增加

心血管疾病 (CVD)、糖尿病和癌症等慢性疾病的迅速流行，是满足复杂治疗需求的客製化和创新药物器材组合产品需求激增的主要因素之一。根据美国国立卫生研究院 (NIH) 的数据，2019 年慢性病死亡人数占所有死亡人数的 74%； 2010 年，死亡人数大幅资料67%。例如，在澳大利亚，澳洲健康与福利研究所报告称，47% 的澳洲人至少患有一种慢性疾病，其中 20% 患有两种或更多慢性疾病。

老年人口不断增加和对个人化医疗的需求

全球老年人数量的不断增加以及人类预期寿命的延长将使老年学面临挑战，从而需要实施药物和补救方法，这进一步支持了药物器械组合产品市场。根据世界卫生组织（WHO）预测，到2030年，每6人中就有1人年龄在60岁以上；届时，总数将达到14亿人。到2050年，该年龄层的人口数量将达到21亿，而80岁及以上的人口将攀升至4.26亿，是2020年的三倍。

药物器材组合产品市场细分：

IMARC Group提供了每个细分市场的主要趋势分析，以及 2024-2032 年全球、区域和国家层面的预测。我们的报告根据产品、应用和最终用户对市场进行了分类。

按产品划分：

  • 药物洗脱支架
  • 透皮贴剂
  • 点滴帮浦
  • 药物洗脱球囊
  • 吸入器
  • 其他的

透皮贴片代表了领先的细分市场

该报告根据产品提供了详细的市场细分和分析。这包括药物洗脱支架、透皮贴片、输液帮浦、药物洗脱球囊、吸入器等。根据该报告，透皮贴片代表了最大的部分。

透皮贴片领域受到对非侵入性药物传递方法不断增长的需求的推动，这些方法提供便利、减轻疼痛并提高患者的依从性。透皮贴片强调以患者为中心的医疗保健解决方案，为传统口服药物和注射剂提供了可行的替代方案，特别是对于有针头恐惧症或吞嚥药片困难的个人而言。此外，该细分市场也受到贴片技术进步的推动，包括开发新型黏合剂配方和渗透增强剂，增强药物透过皮肤的吸收，从而实现更高效、更一致的药物传递。此外，心血管疾病、糖尿病和疼痛相关疾病等慢性疾病的盛行率不断上升，推动了对透皮贴片的需求，因为它们提供缓释製剂，可确保在较长时间内持续治疗药物水平，从而减少了透皮贴片的使用频率。

按应用划分：

  • 心血管
  • 糖尿病
  • 癌症治疗
  • 呼吸系统疾病
  • 其他的

呼吸系统疾病是主要的细分市场

该报告根据应用程式提供了详细的市场细分和分析。这包括心血管、糖尿病、癌症治疗、呼吸系统疾病等。报告称，呼吸系统疾病占最大部分。

呼吸系统疾病领域的驱动因素是全球呼吸系统疾病的盛行率不断上升，而空气污染、吸烟和人口老化等因素又加剧了这种情况。此外，生活方式的改变，包括久坐习惯和不良饮食选择，导致气喘、慢性阻塞性肺病（COPD）和呼吸道感染等呼吸道疾病的发生率上升。此外，都市化和工业化导致人们更接触到环境污染物、过敏原和职业危害，进一步加剧了呼吸道疾病的负担。此外，人们越来越意识到室内和室外空气污染对健康的不利影响，推动了对呼吸治疗和预防措施的需求，从而促进了市场成长。此外，包括影像模式和生物标记检测在内的诊断技术的进步，可以实现呼吸系统疾病的早期检测和干预，透过改善患者的治疗效果和治疗效果来推动市场扩张。

按最终用户划分：

  • 医院
  • 门诊手术中心
  • 其他的

医院代表领先的细分市场

该报告提供了基于最终用户的详细市场细分和分析。这包括电子医院、门诊手术中心等。报告称，医院占最大部分。

医院部门受到对先进医疗设备和技术不断增长的需求的推动，以加强患者护理、优化临床结果并提高营运效率。医院正在投资最先进的设备，例如影像系统、手术机器人和病患监护设备，以满足病患群体不断增长的医疗保健需求。此外，由于对整合资料管理解决方案的需求推动了电子健康记录 (EHR) 和健康资讯系统的采用不断增加，这些解决方案可以简化工作流程、促进明智的决策并确保遵守监管要求。此外，由于医疗保健相关感染 (HAI) 带来的持续挑战以及降低临床环境风险的需要，医院正在优先投资于感染控制和患者安全措施。这包括实施先进的消毒技术、抗菌表面和即时监测系统，以防止感染传播并保障病患的健康。

按地区划分：

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

北美市场领先，占据最大的药物器材组合产品市场份额

该报告还对所有主要区域市场进行了全面分析，其中包括北美（美国和加拿大）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告称，北美是药物器械组合产品最大的区域市场。

北美地区受到糖尿病、心血管疾病和癌症等慢性病盛行率日益上升的推动。随着人口老化的加剧和久坐的生活方式导致慢性病的增加，对创新治疗解决方案的需求不断增加。这一趋势推动了药物器械组合产品的采用，这些产品在管理这些复杂的健康问题方面提供了更高的功效和便利性。此外，该地区受益于强有力的监管框架和简化的审批流程，促进了新组合疗法的开发和商业化。此外，製药公司、医疗器材製造商和研究机构之间的策略合作推动了北美地区的创新并加快了产品开发的步伐。这些合作利用该地区强大的研究基础设施和专业知识来解决未满足的医疗需求并利用新兴市场机会。此外，北美不断增加的医疗保健支出透过提高先进联合疗法的可及性和促进对研发计划的投资来支持市场成长。

（请注意，这只是关键参与者的部分列表，报告中提供了完整列表。）

  • 药物器材组合产品市场的主要参与者积极参与策略性倡议，以保持竞争优势并推动市场成长。这些措施包括广泛的研究和开发 (R&D) 工作，旨在引入新颖的联合疗法，以改善治疗效果并为患者提供便利。此外，公司还致力于透过收购、合作以及与其他行业利益相关者的合作来扩大其产品组合。这些策略联盟使公司能够利用互补的专业知识、技术和资源来加速产品开发和市场渗透。此外，主要参与者正在投资行销和促销活动，以提高对其产品的认识并增强其市场影响力。此外，我们正在努力加强监管合规性和品质保证流程，以确保产品的安全性和有效性。此外，公司正在透过建立当地製造设施和分销网络来探索新兴市场的机会，以满足这些地区对组合产品不断增长的需求。

药物器材组合产品市场新闻：

  • 2020年6月：雅培宣布在美国推出其新型药物器械组合产品FreeStyle Libre 2系统。该系统将雅培的连续血糖监测 (CGM) 技术与可穿戴感测器和行动应用程式整合在一起，使糖尿病患者能够连续监测其血糖水平，而无需进行指尖采血测试。与先前的模型相比，FreeStyle Libre 2 系统提供了更高的准确性和可靠性，为患者提供对其血糖水平的即时了解，并帮助他们就糖尿病管理做出更明智的决策。
  • 2020 年 8 月：美敦力宣布 FDA 批准其 MiniMed 770G 胰岛素帮浦系统用于 2 至 6 岁患有第 1 型糖尿病的儿童。此药物设备组合产品将胰岛素帮浦与连续血糖监测 (CGM) 系统结合，可根据即时血糖读数自动输送胰岛素。 MiniMed 770G 系统采用先进的演算法，有助于稳定幼儿的血糖水平并降低低血糖的风险，让照护者安心并改善儿童糖尿病的整体管理。

本报告回答的关键问题：

  • 迄今为止，全球药物器械组合产品市场表现如何，未来几年将如何表现？
  • 全球药物器材组合产品市场的驱动因素、限制因素和机会是什么？
  • 每个驱动因素、限制因素和机会对全球药物器材组合产品市场有何影响？
  • 主要区域市场有哪些？
  • 哪些国家代表了最具吸引力的药物器材组合产品市场？
  • 基于产品的市场区隔是什么？
  • 药械组合产品市场中哪一款产品最具吸引力？
  • 基于应用的市场区隔是什么？
  • 药械组合产品市场最有吸引力的应用是什么？
  • 基于最终用户的市场区隔是什么？
  • 药物器材组合产品市场中哪一个是最具吸引力的最终用户？
  • 市场竞争结构如何？
  • 全球药物器材组合产品市场的主要参与者/公司有哪些？

本报告回答的关键问题：

  • 迄今为止，全球药物器械组合产品市场表现如何，未来几年将如何表现？
  • 全球药物器材组合产品市场的驱动因素、限制因素和机会是什么？
  • 每个驱动因素、限制因素和机会对全球药物器材组合产品市场有何影响？
  • 主要区域市场有哪些？
  • 哪些国家代表了最具吸引力的药物器材组合产品市场？
  • 基于产品的市场区隔是什么？
  • 药械组合产品市场中哪一款产品最具吸引力？
  • 基于应用的市场区隔是什么？
  • 药械组合产品市场中哪一个应用最有吸引力？
  • 基于最终用户的市场区隔是什么？
  • 药物器材组合产品市场中哪一个是最具吸引力的最终用户？
  • 市场竞争结构如何？
  • 全球药物器材组合产品市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球药物器材组合产品市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依产品

  • 药物洗脱支架
    • 市场趋势
    • 市场预测
  • 透皮贴剂
    • 市场趋势
    • 市场预测
  • 点滴帮浦
    • 市场趋势
    • 市场预测
  • 药物洗脱球囊
    • 市场趋势
    • 市场预测
  • 吸入器
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：按应用

  • 心血管
    • 市场趋势
    • 市场预测
  • 糖尿病
    • 市场趋势
    • 市场预测
  • 癌症治疗
    • 市场趋势
    • 市场预测
  • 呼吸系统疾病
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：依最终用户

  • 医院
    • 市场趋势
    • 市场预测
  • 门诊手术中心
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • Baxter International Inc.
    • Bayer AG
    • Becton Dickinson and Company
    • Boston Scientific Corporation
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Medtronic plc
    • Novartis AG
    • Smith & Nephew plc
    • Stryker Corporation
    • Terumo Corporation
Product Code: SR112024A4751

The global drug device combination products market size reached US$ 155.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 284.9 Billion by 2032, exhibiting a growth rate (CAGR) of 6.7% during 2024-2032. Technological advancements in drug delivery systems, rising prevalence of chronic diseases, increasing geriatric population, surging demand for personalized medicine, strategic collaborations by key players, expanding healthcare expenditure, preference for minimally invasive procedures, and expanding product applications in diverse therapeutic areas are some of the factors supporting the market growth.

Drug Device Combination Products Market Analysis:

  • Major Market Drivers: As per the drug device combination products market analysis, the rising prevalence of chronic diseases and the requirement for more efficient and convenient treatment alternatives are propelling the demand for drug-device combination products. The drug device combination products market growth is also stimulated by the burgeoning geriatric population worldwide, which has surged the demand for new healthcare approaches, as elderly people are producing more lifestyle-related health problems. Additionally, companies have increasingly adopted approaches to personalized medicine, including drug delivery gadgets for targeted therapy, which is further positively contributing to the drug device combination products market share. Other factors that have fueled the drug device combination products market outlook include regulatory support and economic incentives for combination product development, as well as expanding healthcare spending in developing countries.
  • Key Market Trends: As per the drug device combination products market research, the most substantial trends in the drug-device combination products are the growing interest in wearable drug delivery devices for the patient's mobility and quality of life improvement. Another factor that propels the drug device combination products market value is the increasing use of smart devices to control patient adherence and therapy response and adjust the dose and treatment regime as necessary in real-time. In line with this, the incorporation of digital technology into products and their ability to utilize the Internet of Things (IoT) increases patient engagement and outcomes monitoring, which is further driving the drug device combination products market demand. Apart from this, the progression of three-dimensional (3D) printing technology creates new opportunities for individualizing device manufacturing based on patient anatomy and needs, which is contributing to the drug device combination products market forecast.
  • Geographical Trends: As per the drug device combination products market research report, North America is the leading region in the industry due to the developed healthcare infrastructure, extensive investment in research and development (R&D), and lenient regulation. Besides this, the high health expenditure supported by the massive burden of diseases in the region has driven adoption of new and emerging treatment alternatives, which is further accelerating the drug device combination products market price. Europe is a close follower in the drug device combination products market segmentation, given its strong healthcare systems and focus on quality and safety. On the other hand, the Asia-Pacific region is an increasingly growing market supported by rising health expenditure, increasing knowledge of modern treatment approaches, and a growing number of chronic conditions, which is further boosting the drug device combination products market revenue.
  • Competitive Landscape: As per the drug device combination products market statistics, some of the key players in the market include Abbott Laboratories, Baxter International Inc., Bayer AG, Becton Dickinson and Company, Boston Scientific Corporation, GlaxoSmithKline plc, Johnson & Johnson, Medtronic plc, Novartis AG, Smith & Nephew plc, Stryker Corporation, Terumo Corporation, etc.
  • Challenges and Opportunities: As per the drug device combination products market overview, the market has many challenges, including the high level of regulatory requirements, which can lead to an increase in development time and as a result, increase the cost. Ensuring the compatibility of the drug and device, which must meet all safety and effectiveness standards, is a big difficulty. Many of the same factors present opportunities for innovation. In particular, new approaches to increasing the efficiency of devices and increasing the convenience for the patient. A favorable opportunity is also to replenish the market for countries with a potential demand for advanced medical solutions that are not being solved.

Drug Device Combination Products Market Trends:

Technological Advancements in Drug Delivery Systems

New drug delivery systems, including auto-injectors, inhalers, and infusion pumps, are transforming the way healthcare is administered, making it more precise, convenient, and effective. Precise and targeted drug delivery allows patients to achieve the desired therapeutic effect with a minimal likelihood of suffering from adverse drug reactions. For example, using auto-injectors has significantly changed the way patients take medication daily by allowing users to administer it themselves in a comfortable and easy way. This drug delivery system assists with treatment compliance and hospitalization costs cutting. Sophisticated inhalers for respiratory problems, such as those equipped with a dose counter or digital sensors, provide feedback and monitoring, giving patients the power to manage drug administration independently.

Increasing Prevalence of Chronic Diseases

The burgeoning prevalence of chronic diseases, such as cardiovascular disorders (CVDs), diabetes, and cancer, is one of the primary factors that have surged the demand for customized and innovative drug device combination products for complex therapeutic needs. Based on the National Institute of Health (NIH), chronic conditions accounted for 74% of all deaths in 2019; a substantial rise on 67% of deaths in 2010. Mortality data illustrate high prevalence's of chronic conditions among populations. In Australia, for example, Australian Institute of Health and Welfare reports 47% of Australians have at least one chronic disease with 20% bearing 2 or more.

Rising Geriatric Population and Demand for Personalized Medicine

The growing number of geriatric people worldwide and extended human life expectancy will make it challenging to deal with gerontology allowing for the need for medicine implemented and remedy methods, which is further supporting the drug device combination products market. According to the World Health Organization (WHO), 1 of 6 individuals will be aged 60 and above by 2030; at that point, the total number will reach 1.4 billion. By 2050, the number of people in that age category will be 2.1 billion, while the group aged 80 and even older will climb to 426 million, which is three times more in comparison to 2020.

Drug Device Combination Products Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, application, and end user.

Breakup by Product:

  • Drug Eluting Stents
  • Transdermal Patches
  • Infusion Pumps
  • Drug Eluting Balloon
  • Inhalers
  • Others

Transdermal patches represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the product. This includes drug eluting stents, transdermal patches, infusion pumps, drug eluting balloon, inhalers, and others. According to the report, transdermal patches represented the largest segment.

The transdermal patches segment is driven by the increasing demand for non-invasive drug delivery methods that offer convenience, pain reduction, and improved patient compliance. With an emphasis on patient-centric healthcare solutions, transdermal patches provide a viable alternative to traditional oral medications and injections, particularly for individuals with needle phobia or difficulty swallowing pills. Additionally, the segment is propelled by advancements in patch technology, including the development of novel adhesive formulations and permeation enhancers, which enhance drug absorption through the skin, leading to more efficient and consistent drug delivery. Moreover, the rising prevalence of chronic diseases, such as cardiovascular disorders, diabetes, and pain-related conditions, drives the demand for transdermal patches as they offer sustained release formulations that ensure continuous therapeutic levels of medication over an extended period, reducing the frequency of dosing and minimizing fluctuations in drug concentration in the bloodstream.

Breakup by Application:

  • Cardiovascular
  • Diabetes
  • Cancer Treatment
  • Respiratory Diseases
  • Others

Respiratory diseases represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the application. This includes cardiovascular, diabetes, cancer treatment, respiratory diseases, and others. According to the report, respiratory diseases represented the largest segment.

The respiratory diseases segment is driven by the increasing prevalence of respiratory disorders globally, exacerbated by factors such as air pollution, smoking, and aging populations. Moreover, lifestyle changes, including sedentary habits and poor dietary choices, contribute to the rising incidence of respiratory ailments such as asthma, chronic obstructive pulmonary disease (COPD), and respiratory infections. Additionally, urbanization and industrialization lead to heightened exposure to environmental pollutants, allergens, and occupational hazards, further escalating the burden of respiratory diseases. Furthermore, the growing awareness about the adverse health effects of indoor and outdoor air pollution drives demand for respiratory therapies and preventive measures, fostering market growth. Moreover, advancements in diagnostic techniques, including imaging modalities and biomarker assays, enable early detection and intervention for respiratory conditions, driving market expansion through improved patient outcomes and treatment efficacy.

Breakup by End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Hospitals represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the end user. This includes e- hospitals, ambulatory surgical centers, and others. According to the report, hospitals represented the largest segment.

The hospitals segment is driven by the increasing demand for advanced medical devices and technologies to enhance patient care, optimize clinical outcomes, and improve operational efficiency. Hospitals are investing in state-of-the-art equipment such as imaging systems, surgical robots, and patient monitoring devices to meet the growing healthcare needs of their patient populations. Additionally, the adoption of electronic health records (EHRs) and health information systems is on the rise, driven by the need for integrated data management solutions that streamline workflows, facilitate informed decision-making, and ensure compliance with regulatory requirements. Furthermore, hospitals are prioritizing investments in infection control and patient safety measures, spurred by the ongoing challenges posed by healthcare-associated infections (HAIs) and the need to mitigate risks in clinical environments. This includes the implementation of advanced disinfection technologies, antimicrobial surfaces, and real-time monitoring systems to prevent the spread of infections and safeguard patient well-being.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest drug device combination products market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for drug device combination products.

The North American region is driven by the increasing prevalence of chronic diseases, such as diabetes, CVDs, and cancer. With a growing aging population and sedentary lifestyles contributing to the rise in chronic conditions, there's a heightened demand for innovative treatment solutions. This trend fuels the adoption of drug device combination products that offer enhanced efficacy and convenience in managing these complex health issues. Additionally, the region benefits from robust regulatory frameworks and streamlined approval processes, facilitating the development and commercialization of new combination therapies. Moreover, strategic collaborations between pharmaceutical companies, medical device manufacturers, and research institutions drive innovation and accelerate the pace of product development in North America. These collaborations leverage the region's strong research infrastructure and expertise to address unmet medical needs and capitalize on emerging market opportunities. Furthermore, the increasing healthcare expenditure in North America supports market growth by improving accessibility to advanced combination therapies and fostering investment in research and development initiatives.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the drug device combination products industry include Abbott Laboratories, Baxter International Inc., Bayer AG, Becton Dickinson and Company, Boston Scientific Corporation, GlaxoSmithKline plc, Johnson & Johnson, Medtronic plc, Novartis AG, Smith & Nephew plc, Stryker Corporation, Terumo Corporation, etc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • The key players in the drug device combination products market are actively engaged in strategic initiatives to maintain their competitive edge and drive market growth. These initiatives include extensive research and development (R&D) efforts aimed at introducing novel combination therapies that offer improved therapeutic outcomes and patient convenience. Additionally, companies are focusing on expanding their product portfolios through acquisitions, partnerships, and collaborations with other industry stakeholders. These strategic alliances enable companies to leverage complementary expertise, technologies, and resources to accelerate product development and market penetration. Moreover, key players are investing in marketing and promotional activities to raise awareness about their products and enhance their market presence. Furthermore, efforts are being made to strengthen regulatory compliance and quality assurance processes to ensure product safety and efficacy. Additionally, companies are exploring opportunities in emerging markets by establishing local manufacturing facilities and distribution networks to cater to the growing demand for combination products in these regions.

Drug Device Combination Products Market News:

  • In June 2020: Abbott announced the launch of its new drug device combination product, the FreeStyle Libre 2 system, in the United States. This system integrates Abbott's continuous glucose monitoring (CGM) technology with a wearable sensor and a mobile app, allowing individuals with diabetes to monitor their glucose levels continuously without the need for fingerstick tests. The FreeStyle Libre 2 system offers improved accuracy and reliability compared to previous models, providing patients with real-time insights into their glucose levels and helping them make more informed decisions about their diabetes management.
  • In August 2020: Medtronic announced the FDA approval of its MiniMed 770G insulin pump system for use in children aged 2 to 6 years with type 1 diabetes. This drug device combination product combines an insulin pump with a continuous glucose monitoring (CGM) system, enabling automated insulin delivery based on real-time glucose readings. The MiniMed 770G system features advanced algorithms that help stabilize blood sugar levels and reduce the risk of hypoglycemia in young children, providing caregivers with peace of mind and improving the overall management of pediatric diabetes.

Key Questions Answered in This Report:

  • How has the global drug device combination products market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global drug device combination products market?
  • What is the impact of each driver, restraint, and opportunity on the global drug device combination products market?
  • What are the key regional markets?
  • Which countries represent the most attractive drug device combination products market?
  • What is the breakup of the market based on the product?
  • Which is the most attractive product in the drug device combination products market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the drug device combination products market?
  • What is the breakup of the market based on the end user?
  • Which is the most attractive end user in the drug device combination products market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global drug device combination products market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Drug Device Combination Products Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Drug Eluting Stents
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Transdermal Patches
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Infusion Pumps
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Drug Eluting Balloon
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Inhalers
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Cardiovascular
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Diabetes
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Cancer Treatment
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Respiratory Diseases
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ambulatory Surgical Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Baxter International Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bayer AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Becton Dickinson and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Boston Scientific Corporation
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 GlaxoSmithKline plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Johnson & Johnson
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Medtronic plc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Novartis AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Smith & Nephew plc
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Stryker Corporation
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Terumo Corporation
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Drug Device Combination Products Market: Major Drivers and Challenges
  • Figure 2: Global: Drug Device Combination Products Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Drug Device Combination Products Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Drug Device Combination Products Market: Breakup by Product (in %), 2023
  • Figure 5: Global: Drug Device Combination Products Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Drug Device Combination Products Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Drug Device Combination Products Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Drug Device Combination Products (Drug Eluting Stents) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Drug Device Combination Products (Drug Eluting Stents) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Drug Device Combination Products (Transdermal Patches) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Drug Device Combination Products (Transdermal Patches) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Drug Device Combination Products (Infusion Pumps) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Drug Device Combination Products (Infusion Pumps) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Drug Device Combination Products (Drug Eluting Balloon) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Drug Device Combination Products (Drug Eluting Balloon) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Drug Device Combination Products (Inhalers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Drug Device Combination Products (Inhalers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Drug Device Combination Products (Other Products) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Drug Device Combination Products (Other Products) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Drug Device Combination Products (Cardiovascular) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Drug Device Combination Products (Cardiovascular) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Drug Device Combination Products (Diabetes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Drug Device Combination Products (Diabetes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Drug Device Combination Products (Cancer Treatment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Drug Device Combination Products (Cancer Treatment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Drug Device Combination Products (Respiratory Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Drug Device Combination Products (Respiratory Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Drug Device Combination Products (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Drug Device Combination Products (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Drug Device Combination Products (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Drug Device Combination Products (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Drug Device Combination Products (Ambulatory Surgical Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Drug Device Combination Products (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Drug Device Combination Products (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Drug Device Combination Products (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: North America: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: North America: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: United States: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: United States: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Canada: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Canada: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Asia-Pacific: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Asia-Pacific: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: China: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: China: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Japan: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Japan: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: India: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: India: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: South Korea: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: South Korea: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Australia: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Australia: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Indonesia: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Indonesia: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Others: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Others: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Europe: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Europe: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Germany: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Germany: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: France: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: France: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: United Kingdom: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: United Kingdom: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Italy: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Italy: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Spain: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Spain: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Russia: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Russia: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Latin America: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Latin America: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Brazil: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Brazil: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Mexico: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Mexico: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Others: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Others: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Middle East and Africa: Drug Device Combination Products Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Middle East and Africa: Drug Device Combination Products Market: Breakup by Country (in %), 2023
  • Figure 84: Middle East and Africa: Drug Device Combination Products Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Global: Drug Device Combination Products Industry: SWOT Analysis
  • Figure 86: Global: Drug Device Combination Products Industry: Value Chain Analysis
  • Figure 87: Global: Drug Device Combination Products Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Drug Device Combination Products Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Drug Device Combination Products Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Drug Device Combination Products Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 4: Global: Drug Device Combination Products Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Drug Device Combination Products Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Drug Device Combination Products Market: Competitive Structure
  • Table 7: Global: Drug Device Combination Products Market: Key Player